View Older Stories View More Recent Stories

Apr 15, 2026 05:25AM Johnson & Johnson (JNJ) PT Raised to $251 at Bernstein SocGen Group
Apr 14, 2026 05:09PM Johnson & Johnson (JNJ) PT Raised to $265 at RBC Capital
Apr 14, 2026 06:45AM Johnson & Johnson beats estimates, raises 2026 guidance
Apr 14, 2026 06:23AM Johnson & Johnson (JNJ) Raises Quarterly Dividend 3.1% to $1.34; 2.3% Yield
Apr 14, 2026 06:22AM Johnson & Johnson (JNJ) Tops Q1 EPS by 2c, Beats on Revenue; Offers FY Guidance
Apr 14, 2026 02:00AM Johnson & Johnson Q1 earnings preview: analysts eye pharma strength, legal overhang
Apr 13, 2026 11:08AM Johnson & Johnson (JNJ) call put ratio 1.5 calls to 1 put into quarter results
Apr 13, 2026 05:05AM Johnson & Johnson (JNJ) call put ratio 1 call to 1.1 puts into quarter results
Apr 10, 2026 08:01AM Johnson & Johnson presents clinical data for TECNIS PureSee lens at ASCRS
Apr 8, 2026 04:43AM TD Cowen Assumes Johnson & Johnson (JNJ) at Buy
Apr 7, 2026 08:05AM Johnson & Johnson launches VARIPULSE Pro in Europe with CE Mark approval
Apr 1, 2026 12:52PM Johnson & Johnson receives permanent billing code for bladder cancer treatment
Mar 30, 2026 07:16AM Royalty Pharma partners with J&J on $500M drug development deal
Mar 30, 2026 04:21AM J&J reports one-year ICOTYDE psoriasis treatment data shows sustained results
Mar 25, 2026 07:26AM Nanobiotix stock jumps on takeover report involving J&J
Mar 23, 2026 07:45AM TuHURA names former J&J oncology executive as chief medical officer
Mar 19, 2026 06:33AM Guggenheim Reiterates Buy Rating on Johnson & Johnson (JNJ)
Mar 18, 2026 11:26AM BofA Securities remains Neutral on Johnson & Johnson (JNJ): early Ico approval was 'modest upside'
Mar 18, 2026 11:23AM Morgan Stanley stays Overweight on Johnson & Johnson (JNJ) following 'expected positive' Ico approval
Mar 18, 2026 08:43AM Wolfe Research stays Outperform on Johnson & Johnson (JNJ): focus shifts to upcoming h2h trial data
Mar 17, 2026 03:03PM Johnson & Johnson wins new trial on punitive damages in baby powder case
Mar 13, 2026 12:36PM J&J reports 89% response rate in bladder cancer drug trial
Mar 5, 2026 11:30PM This pharma giant is positioned for earnings beats as new drug cycle gains pace
Mar 2, 2026 04:53PM Johnson & Johnson (JNJ) PT Raised to $253 at BofA Securities
Feb 26, 2026 02:31PM Johnson & Johnson reports phase 1b results for prostate cancer drug combo
Feb 24, 2026 05:59AM Increasing unusual call option volume: GSL IGV PBRA EC JNJ PRGS GNW BGS CG IBRX REAL PRMB
Feb 23, 2026 03:59AM Johnson & Johnson reports 3-year TREMFYA data for ulcerative colitis
Feb 19, 2026 05:00PM Johnson & Johnson reports positive trial results for head and neck cancer drug
Feb 19, 2026 02:19PM J&J Is Said To Explore $20b-plus Sale Of Orthopedics Unit - Bloomberg
Feb 18, 2026 10:15AM Johnson & Johnson invests over $1 billion in Pennsylvania cell therapy facility
Feb 13, 2026 04:18PM Philadelphia jury awards $250,000 against J&J in baby powder trial
Feb 13, 2026 02:40PM Johnson & Johnson ordered to pay $250,000 in talc powder lawsuit
Feb 13, 2026 02:34PM Pennsylvania jury finds Johnson & Johnson liable for woman's ovarian cancer - Attorney for National Talc Plaintiffs
Feb 9, 2026 04:46AM Johnson & Johnson reports early pilot study results for atrial fibrillation device
Feb 3, 2026 08:51AM Johnson & Johnson (JNJ) PT Raised to $255 at RBC Capital
Jan 30, 2026 10:07AM J&J's AKEEGA gets EU panel backing for prostate cancer expansion
Jan 28, 2026 01:02AM Morgan Stanley Upgrades Johnson & Johnson (JNJ) to Overweight
Jan 27, 2026 03:50PM FDA approves Johnson & Johnson's DARZALEX FASPRO quadruplet for myeloma
Jan 27, 2026 09:38AM Johnson & Johnson (JNJ) PT Raised to $220 at Freedom Capital Markets
Jan 22, 2026 09:07AM 'Johnson & Johnson (JNJ) Well Positioned To Generate Sustained Momentum'; PT Raised at TD Cowen
Jan 22, 2026 08:39AM RBC Capital Defends Johnson & Johnson (JNJ) Amid Talc Concerns
Jan 22, 2026 06:49AM Guggenheim Reiterates Buy Rating on Johnson & Johnson (JNJ)
Jan 22, 2026 05:16AM Johnson & Johnson (JNJ) PT Raised to $220 at Stifel
Jan 22, 2026 05:12AM Johnson & Johnson (JNJ) PT Raised to $221 at BofA Securities
Jan 22, 2026 05:12AM Johnson & Johnson (JNJ) PT Raised to $221 at BofA Securities
Jan 22, 2026 04:55AM Johnson & Johnson (JNJ) PT Raised to $237 at Raymond James
Jan 21, 2026 08:28AM Johnson & Johnson (JNJ) Meets EPS Estimate, Beats on Revenue; Offers FY Guidance
Jan 21, 2026 04:00AM Oncology, immunology gains to drive J&J Q4 results as investors weigh legal risks
Jan 20, 2026 10:52AM Johnson & Johnson (JNJ) call put ratio 1 call to 1 put into quarter results
Jan 20, 2026 05:10AM Johnson & Johnson (JNJ) call put ratio 2.2 calls to 1 put into quarter results
View More Recent Stories View Older Stories